The paper provides a systematic analysis of modern literature sources that describe the experience with superselective intra-arterial administration of cytostatic drugs in the treatment of locally advanced cervical cancer (LACC). New administration procedures and antitumor therapy regimens in the combination treatment of LACC have been developed and studied in the past 10 years. Neoadjuvant chemotherapy has been proven to open the prospect of surgical treatment for this group of patients. At the same time, the combination treatment can improve five-year disease-free and overall survival rates. However, the cytostatic effect of systemic combination chemotherapy affects not only tumor tissues, but also intact ones, which increases the frequency and severity of complications. Under these conditions, it seems very important to enhance the local efficiency of antitumor therapy without increasing its overall toxicity. The development and introduction of X-ray endovascular surgical interventions in different fields of medicine have prompted scientists to study the possibility of using the regional administration of cytostatics into the tumor feeding vessels in LACC. The use of a high-tech treatment, such as superselective intra-arterial chemotherapy, is one of the possible ways to optimize the results of combination treatment for LACC. The clinical efficiency of intra-arterial chemotherapy is based on the design of a higher-concentration chemotherapy drug in the tumor, which is 10—100 times higher than that of systemic drug administration. At the same time, there is a decrease in the drug concentration in the circulatory system, which leads to reduced chemotherapy toxicity. However, recommendations for using regional chemotherapy for LACC, its regimens, criteria for assessing the clinical tumor response to cytostatics, and optimal conditions for a radical surgical intervention have not been developed so far.